Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisdexamfetamine for acute methamphetamine withdrawal
ACTRN12624001061527Phase 4Recruiting
- Sponsor
- St Vincent's Hospital Sydney
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Stimulant Withdrawal and methamphetamine use disorder (MUD) comparing Lisdexamfetamine taper plus standard care with Matched placebo plus standard care (2 arms). Primary endpoint: Efficacy for acute methamphetamine withdrawal symptoms at Day 7. Started Jul 2025; status: recruiting.
02
Drugs
lisdexamfetamine
03
Conditions
Stimulant Withdrawalmethamphetamine use disorder (MUD)
Beyond the preview
Go deeper on ACTRN12624001061527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001061527.